Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis & Forecast: 2026-2033

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Size and Trends: 2023-2026

The Italy Peptide Receptor Radionuclide Therapy (PRRT) Market is estimated to be valued at USD 42 Mn in 2026 and is expected to reach USD 86.1 Mn by 2033, growing at a compound annual growth The rate (CAGR) of 10.8% from 2026 to 2033.

Key Takeaways

• Based on Drug Type, the Lutetium (Lu-177)-based segment is expected to lead the market with 79.30%share in 2026, due to the widespread clinical adoption of Lu‑177 radiopharmaceuticals.
• Based on Indication, the Gastroenteropancreatic Neuroendocrine Tumor segment is expected to hold 64.20%share of the market in 2026 reflecting the high prevalence and clinical preference for PRRT in treating GEP‑NETs.
• Based on Distribution Channel, the Hospital Pharmacies segment is expected to hold 71.80% share of the market in 2026 supported by the requirement for hospital‑based radiopharmaceutical handling and administration expertise.

Market Overview

The Italy Peptide Receptor Radionuclide Therapy (PRRT) Market is advancing significantly, driven by its critical role in the targeted treatment of neuroendocrine tumors (NETS) and the expansion of specialized nuclear medicine facilities. The increasing demand for precision oncology and the adoption of standardized clinical guidelines, such as those from the Italian Association of nuclear medicine (AIMN), are expected to drive market growth over the forecast period.

Italy’s PRRT solutions are high-precision molecular therapies mainly categorized as Lutetium (Lu-177) or Yttrium-90 systems that deliver concentrated, cytotoxic radiation directly to the tumor site, allowing clinicians to treat complex malignancies with superior efficacy and clarity.  These treatments play a crucial role in modern healthcare for managing inoperable or metastatic Gastroenteropancreatic neoplasms. This is due to their ability to provide localized therapy that spares healthy tissue and improves patient survival with prolonged interventions.

The ongoing innovation in radiolabeled peptides and integrated diagnostic imaging technology like Ga-68 PET/CT scans is reshaping the nuclear medicine industry. The demand for flexible, high-performance theranostic systems is increasing across major Italian hospitals and oncology research centers. These advancements have expanded the functional scope of PRRT by enhancing tumor visualization, ensuring compatibility with personalized dosimetry, and enabling precise adjustment of treatment protocols. The top players operating in the industry are focused on forming strategic acquisitions and launching isotope-integrated platforms designed mainly for streamlined digital workflows and personalized cancer interventions.

Current Events and Its Impacts on the Italy Peptide Receptor Radionuclide Therapy (PRRT) Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Insights, By Drug Type – Lutetium (Lu-177)-based Leads Due to its Widespread Clinical Adoption

In terms of drug type, the Lutetium (Lu-177)-based segment contributes the highest share of 79.30% in 2026 of the Italy Peptide Receptor Radionuclide Therapy (PRRT) Market. This leadership is sustained by the clinical maturity of 177Lu DOTATATE which has become the primary therapeutic choice due to its favorable safety profile and precise beta particle emission. The ongoing investments in Italian nuclear medicine facilities have streamlined the handling of this isotope, thus ensuring it remains the preferred option over older alternatives. In addition, the development of no-carrier-added Lutetium-177 has improved the specific activity of these drugs. This has allowed for more effective targeting of small tumor lesions. Consequently, the Italian healthcare system continues to favor Lutetium (Lu-177)-based protocols due to their strong therapeutic efficacy and reduced risk of renal toxicity.

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Insights, By Indication – Gastroenteropancreatic Neuroendocrine Tumor Leads with high Prevalence and Clinical Preference for PRRT in Treating GEP ‑ NETs

In terms of indication, the gastroenteropancreatic neuroendocrine tumor segment contributes the highest share of 64.20% in the Italy Peptide Receptor Radionuclide Therapy (PRRT) Market in 2026. This is owing to the increasing incidence of gastroenteropancreatic neuroendocrine tumors in Italy. This compliance is reinforced by the Italian Association of Medical Oncology (AIOM) guidelines, which recommend PRRT for patients with advanced, well-differentiated GEP NETs that have progressed on standard somatostatin analogs. The segment's growth is further accelerated by the introduction of PRRT for Grade 3 (G3) neuroendocrine neoplasms, widening the eligible patient pool. In addition, Italy's specialized network of NET Centers of Excellence ensures that patients receive early access to these targeted radioligand therapies. Because GEP-NETs consistently overexpress the somatostatin receptors targeted by these drugs, this indication remains the cornerstone of the PRRT effect.

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Insights, By Distribution Channel – Hospital Pharmacies Leads with Administration Expertise

In terms of distribution channel, the hospital pharmacies contributes the highest share of 71.80% in the Italy Peptide Receptor Radionuclide Therapy (PRRT) Market in 2026. This is because the administration of PRRT is strictly limited to specialized clinical settings. These facilities are equipped with the radioprotection infrastructure and hot labs that are required to store and prepare radioactive substances safely. The Italian National Health Service (SSN) manages the procurement of these high-cost therapies via hospital-based central purchasing, which ensures strict regulatory compliance and patient safety. Hospital pharmacists play a key operational role in aligning just-in-time delivery schedules with the short physical half-life of the radioisotopes, ensuring clinical and logistical efficiency. As a result, the centralized nature of nuclear medicine in Italy reinforces the hospital pharmacy as the indispensable hub for PRRT logistics and dispensing.

Market Report Scope

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Drivers

Rising incidence of neuroendocrine tumors

The increasing incidence of neuroendocrine tumors (NETs) is a primary catalyst for the growth of the Italy Peptide Receptor Radionuclide Therapy (PRRT) market. NETs have seen a substantial rise in documented cases across Italy, with recent epidemiological data suggesting nearly a sevenfold increase in detection over the last few decades. The rise is attributable to the growing availability and utilization of high-resolution diagnostic imaging like Gallium 68 PET/CT, thus enabling the identification of subclinical lesions. As more patients are diagnosed with advanced or metastatic gastroenteropancreatic tumors, the clinical demand for targeted interventions like PRRT has intensified. It has become an essential second-line treatment because PRRT offers a precise mechanism for delivering cytotoxic radiation directly to tumor cells expressing somatostatin receptors

Analyst Opinion (Expert Opinion)

• The Italy PRRT market demonstrates steady expansion, driven by increasing clinical acceptance of targeted radiopharmaceutical therapies for neuroendocrine tumors (NETs). PRRT has become an established therapeutic option for patients with somatostatin receptor–positive gastroenteropancreatic NETs, particularly in cases where surgery is not viable or disease has progressed after conventional treatments.
• Clinical data continue to underpin market momentum. Large multicenter studies and Italian institutional cohorts report disease control rates exceeding 80% following treatment with lutetium-177–based PRRT, along with progression-free survival extending beyond three years in selected patient groups. These outcomes have reinforced PRRT’s inclusion in national and European treatment guidelines, supporting consistent procedural volumes across specialized centers.
• Epidemiological factors also contribute to sustained demand. Neuroendocrine tumors in Italy are estimated to occur at approximately 6 cases per 100,000 population, with gastroenteropancreatic NETs accounting for the largest share of PRRT-eligible patients. Adoption is strongest in northern and central regions, where advanced nuclear medicine infrastructure and referral networks are well developed.
• Despite favorable clinical performance, the market remains constrained by high therapy complexity, specialized radiopharmaceutical production requirements, and the need for dedicated facilities. Nevertheless, ongoing expansion of nuclear medicine capabilities and continued clinical validation are expected to strengthen PRRT’s role within Italy’s oncology treatment landscape.

Italy Peptide Receptor Radionuclide Therapy (PRRT) Industry News

• In February 2025, the Italian Association of Nuclear Medicine, Molecular Imaging and Therapy (AIMN) published a comprehensive guide in the journal Clinical and Translational Imaging. This guide centers on the administration of peptide receptor radionuclide therapy (PRRT) using [Lu]Lu-Oxodotreotide for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The guideline represents a step toward enhanced clinical standardization and the implementation of PRRT techniques throughout Italy.

Market Segmentation

• Drug Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Lutetium (Lu-177)-based      
  • Yttrium (Y-90)-based
• Indication Insights (Revenue, USD Mn, 2026 - 2033)
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Foregut Neuroendocrine Tumor
  • Midgut Neuroendocrine Tumor
  • Hindgut Neuroendocrine Tumor
• Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
• Key Players Insights
  • Novartis International AG
  • Curium Pharma
  • ITM Isotope Technologies Munich SE
  • Eckert & Ziegler AG

Sources

Primary Research Interviews

• Nuclear Medicine Physicians (PRRT Specialists)
• Oncologists Specialized in Neuroendocrine Tumors (NETs)
• Radiopharmaceutical Manufacturers & Developers
• Cyclotron & Radiochemistry Facility Operators
• Hospital Nuclear Medicine Department Heads (Italy)
• Healthcare Technology Assessment (HTA) Experts
• Others

Databases

• Bloomberg Terminal
• Thomson Reuters Eikon
• IQVIA Oncology Database
• Evaluate Pharma
• Others

Magazines

• Nuclear Medicine Communications
• European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) News
• Oncology Times Europe
• Pharma Manufacturing Europe
• Healthcare Executive Italy
• Others

Journals

• European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI)
• Journal of Nuclear Medicine (JNM)
• Clinical Nuclear Medicine
• Theranostics
• The Lancet Oncology
• Annals of Oncology
• Others

Newspapers

• Il Sole 24 Ore (Healthcare & Pharma Section)
• Financial Times
• Reuters
• Bloomberg News
• Corriere della Sera – Health & Science
• Others

Associations

• Italian Association of Nuclear Medicine (AIMN)
• European Association of Nuclear Medicine (EANM)
• Italian Association of Medical Oncology (AIOM)
• European Society for Medical Oncology (ESMO)
• International Atomic Energy Agency (IAEA) – Nuclear Medicine Program
• Others

Public Domain Sources

• Italian Ministry of Health (Ministero della Salute)
• Agenzia Italiana del Farmaco (AIFA)
• European Medicines Agency (EMA)
• Istituto Superiore di Sanità (ISS)
• World Health Organization (WHO)
• OECD Health Statisticsh
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Oncology & Nuclear Medicine Market Intelligence (Last 8 Years)

Definition: The Peptide Receptor Radionuclide Therapy (PRRT) market is a specialized sector of the biopharmaceutical industry that focuses on the development, manufacturing, and distribution of targeted radiopharmaceuticals used to treat specific cancers. This market operates on a theranostic framework, which utilizes radiolabeled peptides to identify and destroy tumor cells that overexpress specific receptors. The primary application of these therapies is for neuroendocrine tumors, where isotopes such as Lutetium-177 deliver localized radiation to malignancy while sparing healthy surrounding tissue. The significant growth in these sectors is currently driven by the increasing global prevalence of rare cancers and the expansion of specialized nuclear medicine facilities. Furthermore, ongoing research into new radioligands and a shift toward personalized oncology are expected to broaden the market’s reach into various solid tumor types.